Impact of Obesity on Plasma Natriuretic Peptide Levels

By Thomas J. Wang, Martin G. Larson, Daniel Levy, Emelia J. Benjamin, E. Leip, Peter W. F. Wilson, Ramachandran S. Vasan. Circulation, 2004

1,004 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Complementary and alternative medicine

View Paper: https://www.semanticscholar.org/paper/481119d32a4680a545ce75b30f8df5b26e34da39

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. G. Fonarow
2. J. Cleland
3. Gerasimos Filippatos
4. E. Braunwald
5. S. Anker
6. C. Yancy
7. M. Gheorghiade
8. Véronique L. Roger

Citations in the corpus

• State of the art: Using natriuretic peptide levels in clinical practice (2008, background): “It appears that ACE inhibitors, angiotensin receptor blockers, spironolactone, and perhaps long-term beta-blockers (in the short-term beta-blockers increase NP levels) drive NP levels down [8–93].”
• Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes. (2012, positive): “A further connection between the NP system and adipose tissue is highlighted by the fact that obese human subjects with metabolic syndrome often show reduced circulating NPs and biological efficacy (e.g., blood pressure control) (23, 24).”